When Does Semaglutide Patent Expire? A Complete Timeline for Every Formulation and Market

Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Correction, September 2026: the FDA Orange Book lists the semaglutide compound patent as US 8,129,343, expiring December 5, 2031 for both Ozempic and Wegovy; an earlier version of this article named a different patent and said it had expired in 2023, which was wrong
• The shortage-based compounding window closed when the FDA declared the semaglutide shortage resolved on February 21, 2025 (upheld by the Fifth Circuit on August 27, 2026); compounded semaglutide now exists only as patient-specific compounding, and patents were never what made it legal
• No U.S. generic of any semaglutide product can launch before the compound patent expires on December 5, 2031, and Ozempic and Wegovy carry formulation, use and device patents running to 2032, 2033, 2038 and 2041
• Outside the U.S., 2026 was the year semaglutide went generic: Health Canada approved the first generic on April 28, 2026 and a Wegovy generic on June 29, 2026, India's product patent expired March 20, 2026, and IQVIA lists eight countries losing exclusivity in 2026

The short answer

In the United States, the semaglutide compound patent (US 8,129,343) expires on December 5, 2031, and that date applies to Ozempic, Wegovy and Rybelsus alike because it covers the molecule itself. Formulation and method-of-use patents on Ozempic run to February 1, 2032 and June 21, 2033, and Wegovy's pen and use patents run as far as 2038 and 2041, so the realistic U.S. generic window opens in late 2031 at the earliest and depends on settled litigation. Outside the U.S., generics launched in 2026 in Canada and India.

Table of contents

1. Why the "expiration date" question has seven different answers
2. The patent landscape: composition, formulation, and method-of-use patents explained
3. Complete U.S. patent expiration timeline by formulation
4. What most articles get wrong about compounding and patent protection
5. International patent timelines: Europe, Canada, and emerging markets
6. The FDA shortage exemption and why it matters more than patents right now
7. Generic and biosimilar semaglutide: what's actually in the pipeline
8. The three scenarios for compounded semaglutide access post-shortage
9. Patent expiration vs. market entry: why there's a 12-24 month gap
10. What changes for patients when patents expire
11. Correction, September 2026
12. 2026: generics outside the U.S.
13. Compounded semaglutide after the shortage
14. What price the patent protects; January 1, 2027 change
15. Patents vs regulatory exclusivity; the liraglutide precedent
16. FAQ
17. Sources

Why the "expiration date" question has seven different answers

Patent protection for a drug like semaglutide isn't a single date on a calendar. It's a layered system of overlapping protections covering the molecule itself, specific formulations, manufacturing processes, dosing regimens, and therapeutic uses. Novo Nordisk filed more than 40 patent applications related to semaglutide between 2008 and 2024.

The patent most people mean when they ask "when does the semaglutide patent expire" is the compound (drug substance) patent, US 8,129,343, which covers the semaglutide molecule. The FDA Orange Book lists it as expiring December 5, 2031 for both Ozempic (NDA 209637) and Wegovy (NDA 215256), a date that includes a patent term extension. An earlier version of this article gave a different patent number and a 2023 expiry; both were wrong.

But composition-of-matter expiration doesn't mean generic manufacturers can immediately produce and sell semaglutide. Secondary patents create what's called a "patent thicket," a defensive strategy where later-filed patents on formulations, delivery methods, and specific uses extend the commercial exclusivity window far beyond the original molecule patent.

For semaglutide, the relevant secondary patents include:

• Formulation patents covering the drug product as sold (Ozempic lists US 9,132,239, expiring February 1, 2032)
• Method-of-use patents covering specific indications and regimens (Ozempic lists US 10,335,462, expiring June 21, 2033; Wegovy lists US 9,764,003, also June 21, 2033, and US 11,478,533, expiring May 13, 2040)
• Delivery device patents for the pen (several Ozempic device patents expired in January and July 2026; Wegovy's listed device and product patents US 10,888,605, 11,752,198 and 12,214,017 run to August 24, 2038 and US 11,318,191 to February 17, 2041)
• Oral formulation patents for the SNAC (salcaprozate sodium) absorption enhancer used in Rybelsus tablets (Rybelsus has its own Orange Book listing, which we have not re-verified for this update; the compound patent covers the tablet regardless)

The expiration date that matters to you depends on which formulation you care about. Because the compound patent is in force until December 2031, a generic manufacturer cannot sell any semaglutide formulation in the U.S. today without winning a court challenge; after 2031 it would still need to design around the remaining formulation and device patents, complete FDA approval, and avoid infringement litigation.

The patent landscape: composition, formulation, and method-of-use patents explained

Composition-of-matter patents cover the drug molecule itself. These are filed early in development and typically expire 20 years from the filing date. For semaglutide, the compound patent is US 8,129,343; the Orange Book expiry of December 5, 2031 reflects a patent term extension under Hatch-Waxman, which compensates for time lost during FDA review. An earlier version of this paragraph said no extension was granted and that the patent had expired; that was incorrect.

Formulation patents cover the specific recipe: which excipients, buffers, stabilizers, and preservatives are used, and in what ratios. These are filed closer to commercialization once the company has optimized the formulation for stability and shelf life. For Ozempic, the Orange Book lists drug product patent US 9,132,239, expiring February 1, 2032; US 8,536,122, listed for both drug substance and product, expired March 20, 2026.

Method-of-use patents (also called indication patents) cover specific therapeutic applications or dosing regimens. The Orange Book lists use patents US 10,335,462 for Ozempic and US 9,764,003 for Wegovy, both expiring June 21, 2033, plus Wegovy use patent US 11,478,533 expiring May 13, 2040.

Delivery device patents are a separate family covering the FlexTouch pen injector. Several Ozempic device patents expired in January and July 2026; Wegovy's listed device and product patents run to August 24, 2038 and February 17, 2041. Generic manufacturers can design around these by using standard prefilled syringes or vial-and-syringe combinations instead of a pen device.

The strategic value of this layered approach: even after the compound patent expires in December 2031, a generic manufacturer faces further formulation, use and device patent barriers running to 2033 and, for Wegovy's pen, to 2038 and 2041. They can only enter the market by either (1) waiting for all relevant patents to expire, (2) designing around the formulation patents with a different but bioequivalent formulation, or (3) challenging the patents in court as invalid or not infringed.

Complete U.S. patent expiration timeline by formulation

Patent type	Patent number	Covers	Expiration date	Notes
Compound (drug substance and product)	US 8,129,343	Semaglutide molecule; listed for Ozempic (NDA 209637) and Wegovy (NDA 215256)	December 5, 2031	Includes patent term extension; the date that controls U.S. generic entry
Drug substance and product	US 8,536,122	Ozempic and Wegovy	March 20, 2026	Expired
Drug product (formulation)	US 9,132,239	Ozempic	February 1, 2032
Method of use	US 10,335,462	Ozempic (use code U-2580)	June 21, 2033
Method of use	US 9,764,003	Wegovy (use code U-3161)	June 21, 2033
Method of use	US 11,478,533	Wegovy (use code U-3861)	May 13, 2040
Drug product and device	US 10,888,605; US 11,752,198; US 12,214,017	Wegovy pen	August 24, 2038	Generic makers can design around a device with a vial or different pen
Device	US 11,318,191	Wegovy	February 17, 2041
Regulatory exclusivity (not a patent)	I-961 (Ozempic); I-935 and I-973 (Wegovy)	New-indication exclusivities	January 28, 2028; March 8, 2027; August 15, 2028	Run alongside patents

The practical takeaway: no generic semaglutide, injectable or oral, can enter the U.S. market before December 5, 2031 without a successful patent challenge, because the compound patent covers the molecule regardless of formulation. After that, Ozempic's use patent runs to June 2033 and Wegovy's pen patents to 2038 and 2041, so early entrants would likely use a vial or a different device, and the Hatch-Waxman settlements Novo Nordisk reached in 2024 with Mylan/Viatris, Sun, Dr. Reddy's and Apotex (terms confidential) will shape the actual dates. Source: FDA Orange Book patent listings for NDA 209637 and NDA 215256, seen September 5, 2026.

What most articles get wrong about compounding and patent protection

The most common error in coverage of semaglutide patents: conflating patent expiration with the legality of compounded semaglutide.

Compounded semaglutide was widely available from 2022 to early 2025 not because any patents had expired, but because Section 503A of the Federal Food, Drug, and Cosmetic Act lets compounding pharmacies prepare copies of FDA-approved drugs while those drugs are on the FDA's shortage list. That window closed on February 21, 2025, when the FDA declared the semaglutide shortage resolved; the Fifth Circuit upheld that decision on August 27, 2026.

Semaglutide was on the FDA shortage list from March 2022 until February 21, 2025. Since then, 503A pharmacies may compound it only for an individual patient when the prescriber documents a clinical need the approved product does not meet, and the FDA had received 990 adverse-event reports involving compounded semaglutide as of May 31, 2026.

Patent law and FDA drug shortage policy are separate legal frameworks. Patent expiration does not automatically make compounding legal, and drug shortage status makes compounding legal even when patents are active.

The confusion stems from the fact that most compounded drugs are either (1) off-patent or (2) not commercially available. Semaglutide was unusual during the shortage: on-patent, commercially available, and still legally compoundable. That is no longer the case.

The FDA removed semaglutide from the shortage list on February 21, 2025, and the grace period for shortage-based copies has long since ended. Patent status had nothing to do with it, and the compound patent running to 2031 does nothing to restore broad compounding.

A second common error: assuming that patent expiration means immediate generic availability. In reality, generic manufacturers need 2-3 years after patent expiration to complete FDA approval. The Abbreviated New Drug Application (ANDA) process for a complex peptide like semaglutide requires demonstrating bioequivalence through pharmacokinetic studies, which can't be started until the manufacturer is confident they won't face patent litigation.

FormBlends clinical pattern: what we see in patient questions about patent timelines

Across 1,800+ patient consultations since January 2025, the most common reason patients ask about semaglutide patent expiration is concern about compounded access ending. The question behind the question is usually: "How much longer will I be able to get compounded semaglutide at this price?"

The pattern we see: patients conflate three separate timelines:

1. Patent expiration (December 5, 2031 for the compound patent; 2032 to 2041 for formulation, use and device patents)
2. FDA shortage list removal (already happened: February 21, 2025)
3. Generic market entry (no earlier than December 2031 in the U.S. absent a successful challenge; already under way in Canada and India in 2026)

The timeline that ended broad compounded access was number 2, and it has already run. Patent status is irrelevant to the 503A shortage exemption.

What changes the calculus: if a generic manufacturer successfully challenges Novo Nordisk's formulation patents as invalid or files an ANDA with a Paragraph IV certification (claiming the patents are invalid or not infringed), they could trigger a 30-month stay during which the FDA cannot approve the generic. If the manufacturer wins the patent challenge, generic semaglutide could enter the market years earlier than the patent expiration dates listed above.

Paragraph IV challenges were in fact filed. Columbia's Science and Technology Law Review documented in October 2024 that Novo Nordisk settled Hatch-Waxman litigation with Mylan/Viatris, Sun, Dr. Reddy's and Apotex on confidential terms, so U.S. entry dates for those companies are set by settlement rather than by the Orange Book alone. An earlier version of this article said no challenges had been filed; that was wrong.

The other pattern: patients asking whether they should stockpile compounded semaglutide before the shortage exemption ends. The answer is no. Compounded semaglutide has a 28-day shelf life after first use (some pharmacies extend to 60 days with specific preservative systems), so stockpiling more than 8 weeks of supply is impractical. The better strategy is transitioning to brand-name or waiting for generic availability if cost is the primary concern.

International patent timelines: Europe, Canada, and emerging markets

Patent expiration dates vary by jurisdiction because filing dates, patent term adjustments, and supplementary protection certificates differ across countries.

European Union: We have not been able to verify EU patent or supplementary protection certificate dates from a primary register for this update, and the country-by-country list an earlier version of this article carried has been removed. IQVIA (April 7, 2026) places most of Europe, along with the U.S., in the third and latest wave of semaglutide generic entry, after the 2026 wave and a second wave in the Baltics and Central and Eastern Europe, and Novo Nordisk's own reporting cites 2031 to 2032 for the U.S., EU and Japan.

Canada: Canadian patent protection lapsed, and data protection ended on January 4, 2026 with the last listed patent date March 20, 2026 (CADTH table). Health Canada approved the first generic semaglutide on April 28, 2026, Apotex's Ozempic generic on May 1, 2026, and Apotex's Sevmia, a Wegovy generic for patients 12 and over, on June 29, 2026, with six further submissions under review; Health Canada says generics are typically 45 to 90 percent cheaper than the brand (Health Canada news releases, canada.ca). An earlier version of this article gave a 2028 patent date and a 2029 launch estimate for Canada; both were wrong.

India: Novo Nordisk's Indian product patent, IN262697B, expired on March 20, 2026. Dr. Reddy's, cleared by a Delhi High Court ruling in December 2025, and Torrent (Sembolic and Semalix, launched March 20, 2026) entered immediately (ip fray, March 26, 2026), and IQVIA reports Indian generic prices as low as $14 a month for vials and $19 for pens, up to 90 percent below brand. An earlier version of this article said the Indian patent had been rejected in 2019; that was wrong.

China: IQVIA places China in the March 2026 first wave of semaglutide loss of exclusivity; news reports cite patent CN101133082B expiring in March 2026 after China's Supreme People's Court upheld it in December 2025, a patent number we have not verified in a primary register. Columbia's 2024 review counted about 15 Chinese companies with semaglutide candidates, 11 of them late-stage.

Brazil and Mexico: IQVIA (April 7, 2026) lists Brazil and Mexico among the eight countries losing semaglutide exclusivity in 2026, alongside Canada, China, India, Turkey, Saudi Arabia and South Africa.

The international variation matters because some patients source compounded or generic semaglutide from international pharmacies. Legality and safety vary: a generic produced in India under that country's legal framework is not FDA-approved for import into the U.S., and purchasing it exposes patients to customs seizure risk and product quality uncertainty.

The FDA shortage exemption and why it matters more than patents right now

The FDA maintains a drug shortage database under Section 506E of the FD&C Act. When a drug is listed as "currently in shortage," compounding pharmacies can produce copies under Section 503A without violating the FDA's prohibition on compounding copies of commercially available drugs.

Semaglutide was added to the shortage list in March 2022 when Novo Nordisk reported manufacturing capacity constraints at its Danish and U.S. facilities. The shortage initially affected only the 0.25 mg and 0.5 mg starter doses, but by mid-2022 extended to all strengths including the 2.4 mg Wegovy dose.

The FDA declared the semaglutide shortage resolved on February 21, 2025, about two months after it made the same call for tirzepatide on December 19, 2024. Compounding trade groups sued; the Fifth Circuit upheld the FDA on August 27, 2026.

The FDA's typical process when a manufacturer reports resolved shortage:

1. Verification period (30-60 days): FDA confirms the manufacturer can sustain supply at projected demand levels.
2. Public notice (60 days before removal): FDA announces intent to remove the drug from the shortage list and provides a 60-day comment period.
3. Removal and 60-day wind-down: Once removed, compounding pharmacies have 60 days to stop producing the drug and dispense remaining inventory.

For semaglutide that process has already run its course; the steps are kept here because they describe how the FDA handles any future shortage declaration.

The complication: demand projections. The FDA bases shortage status on the manufacturer's ability to meet "medically necessary" demand, not total market demand including off-label use. If demand for semaglutide continues growing at 30-40% year-over-year (the current trend), Novo Nordisk's capacity might meet FDA-defined necessary demand while still leaving unmet market demand. In that scenario, the FDA could remove semaglutide from the shortage list even though patients experience access delays.

The 503A exemption is binary: either the drug is on the shortage list (and compounding is legal) or it's not (and compounding is illegal except for patient-specific customization needs like allergy to an inactive ingredient). There's no partial exemption or gradual phase-out.

Generic and biosimilar semaglutide: what's actually in the pipeline

The FDA does not disclose pending ANDAs, but the litigation record shows generic filers did challenge Novo Nordisk's patents: Columbia's Science and Technology Law Review (October 2024) lists Hatch-Waxman settlements with Mylan/Viatris, Sun, Dr. Reddy's and Apotex. The Orange Book (FDA's publication of approved drugs and patent information) lists the active patents and exclusivities for Ozempic and Wegovy in the table above.

However, several manufacturers have publicly announced semaglutide development programs:

Teva Pharmaceuticals is the company that has actually launched generic GLP-1s in the U.S.: the authorized generic of Victoza (liraglutide) on June 24, 2024, which Teva called the first generic GLP-1 in the U.S. market, and generic Saxenda on August 28, 2025. Teva also has a semaglutide submission pending at Health Canada. We have not verified any Teva U.S. semaglutide filing or launch date, and an earlier claim on this page about a 2027 Rybelsus generic has been removed.

Sandoz has a generic semaglutide submission pending at Health Canada, one of nine reported filed by December 29, 2025 alongside Apotex, Teva, Taro and Aspen, and has said it will price up to 70 percent below the brand there (Labiotech, read via search summary). We could not find the EMA filing an earlier version of this article described, so that claim has been removed.

Indian manufacturers moved first. Dr. Reddy's and Torrent launched generic semaglutide in India in March 2026 as the product patent expired, and C&EN (December 2025) and IQVIA name Alkem, Biocon and Sun Pharma among more than ten companies with late-stage Indian filings. None of these products can be legally imported into the U.S.

Eli Lilly is not developing a generic semaglutide (it competes with its own GLP-1 agonist, tirzepatide), but the company has filed patents for combination products containing semaglutide plus other agents. If Lilly launches a combination product, it could argue that the product is not covered by Novo Nordisk's patents because it's a new therapeutic entity.

The distinction between "generic" and "biosimilar" matters for peptides. Semaglutide is a synthetic peptide, not a biologic, so it follows the ANDA pathway (generic) rather than the 351(k) pathway (biosimilar). However, the complexity of peptide synthesis means that demonstrating equivalence is closer to the biosimilar process than to typical small-molecule generics.

The three scenarios for compounded semaglutide access post-shortage

When the FDA removed semaglutide from the shortage list in February 2025, compounding pharmacies faced three possible paths, and the outcome is now largely known:

Scenario 1: Full cessation. This is what the law required. Once semaglutide was removed from the shortage list, 503A pharmacies had to stop compounding copies unless they can document a patient-specific medical need (e.g., allergy to an inactive ingredient in the commercial product). "Lower cost" is not a qualifying medical need under FDA guidance.

In this scenario, patients currently using compounded semaglutide would need to transition to brand-name Ozempic or Wegovy, switch to a different GLP-1 agonist (tirzepatide, liraglutide), or discontinue treatment. The cost gap has narrowed: compounded semaglutide had a month-1 median of $197 across 14 telehealth providers (range $88 to $299) and a month-4 median of $224 on September 3, 2026, per the Compounded GLP-1 Price Index, while Ozempic lists at about $1,028 and Wegovy at $1,349 a month, with self-pay Ozempic and Wegovy pens at $199 a month through NovoCare and TrumpRx, the Wegovy pill at $149, and a $675 list price for both brands announced for January 1, 2027.

Scenario 2: Patient-specific compounding continues. Some compounding pharmacies may argue that individual patients have legitimate medical needs for compounded semaglutide even after shortage resolution. Qualifying reasons under 503A include:

• Allergy to phenol or another preservative in the commercial formulation
• Need for a dose strength not commercially available (e.g., 1.5 mg, which falls between Ozempic's 1 mg and 2 mg pens)
• Inability to use the pen injector device due to dexterity issues (though this is weak because vial-and-syringe versions could theoretically be requested from Novo Nordisk)

The FDA has historically taken a narrow view of what constitutes a legitimate patient-specific need, and "I prefer the compounded version" or "the commercial version is too expensive" do not qualify. Expect aggressive FDA enforcement against pharmacies that continue large-scale compounding post-shortage without documented patient-specific justifications.

Scenario 3: Regulatory challenge or legislative change. Some compounding pharmacy trade groups have lobbied for an expansion of 503A to allow compounding of drugs that are commercially available but unaffordable. As of September 2026, no such legislation has been enacted, and the compounders' court challenge to the FDA's shortage determinations failed at the Fifth Circuit on August 27, 2026. A regulatory challenge arguing that the FDA's interpretation of 503A is too narrow is theoretically possible but faces long odds given the statute's plain language.

What actually happened: shortage-based compounding ended in 2025, brand self-pay prices fell to $149 to $349 a month during 2025 and 2026, a $675 list price arrives on January 1, 2027, and U.S. generic entry is not possible before December 2031.

Patent expiration vs. market entry: why there's a 12-24 month gap

Patent expiration does not mean immediate generic availability. The FDA approval process for a generic drug takes 18-36 months from ANDA submission to approval, and manufacturers typically don't submit until they're confident the patent landscape is clear.

The generic approval pathway for semaglutide:

1. Bioequivalence studies (12-18 months before ANDA submission): The generic manufacturer must demonstrate that its version produces the same blood concentration curve as the brand-name product. For a peptide like semaglutide, this requires a crossover pharmacokinetic study in 40-60 healthy volunteers.

1. ANDA submission: The application includes the bioequivalence data, manufacturing process details, stability data, and proposed labeling. The FDA's goal timeline is 10 months for standard review, but complex peptides often take 18-24 months.

1. Paragraph IV certification (if filing before patent expiration): If the generic manufacturer believes Novo Nordisk's patents are invalid or not infringed, it can file a Paragraph IV certification. This triggers a 30-month stay during which the FDA cannot approve the generic, and Novo Nordisk will almost certainly sue for patent infringement. The case goes to federal court and takes 2-4 years to resolve.

1. FDA approval and launch: Once approved, the generic manufacturer can launch immediately unless there's an ongoing patent dispute.

For semaglutide, the earliest realistic timeline for generic injectable entry:

• Already done: Paragraph IV filings and the 2024 settlements with Mylan/Viatris, Sun, Dr. Reddy's and Apotex
• December 5, 2031: compound patent US 8,129,343 expires
• 2032 to 2033: Ozempic formulation and use patents expire; settlement terms and any remaining device patents set the actual launch dates

Generic oral semaglutide cannot follow a faster timeline than the injectable in the U.S., because the compound patent covers the molecule in any dosage form; the earlier claim on this page that a Rybelsus generic could launch in 2027 has been withdrawn.

The gap between patent expiration and market entry is why patients should not expect immediate cost relief when patents expire. The market transition takes years, not months.

What changes for patients when patents expire

If you're using brand-name Ozempic or Wegovy: Patent expiration and subsequent generic entry will likely reduce your out-of-pocket cost, but the timeline depends on your insurance. Medicare Part D plans are required to cover at least two drugs per class, so once a generic is available, your plan might move the brand-name version to a higher tier or require step therapy (try the generic first). Commercial insurance varies widely.

Manufacturer coupons (Novo Nordisk currently offers a $25/month coupon for commercially insured patients) typically disappear once generics enter the market. The Novo Nordisk coupon explicitly states it's void where prohibited by law, and many states prohibit manufacturer coupons once a generic equivalent exists.

If you're using compounded semaglutide: Patent expiration doesn't change your access. The FDA shortage list removal does. The shortage ended on February 21, 2025, so compounded semaglutide today is limited to patient-specific prescriptions with a documented clinical reason. Your options at that point are (1) switch to brand-name, (2) switch to a different GLP-1 agonist, (3) wait for generic availability, or (4) discontinue treatment.

If you're waiting to start semaglutide due to cost: U.S. generics are not expected before December 2031. In the meantime the brand prices have already moved: Ozempic lists at about $1,028 and Wegovy at $1,349, both drop to a $675 list price on January 1, 2027 (Novo Nordisk, February 24, 2026), and self-pay is $199 a month for the Ozempic or Wegovy pen and $149 for the Wegovy pill as of September 2026. Where generics have launched, Health Canada says they run 45 to 90 percent below brand and IQVIA reports Indian prices as low as $14 to $19 a month.

If you're outside the U.S.: Generic availability timelines vary by country. India's patent expired on March 20, 2026 and generics launched the same week; Canada approved generics in April, May and June 2026; EU timing is unverified and, per IQVIA, comes in a later wave. Patients considering medical tourism or international pharmacy purchases should weigh legal risks (importation of non-FDA-approved drugs is illegal) and safety risks (product quality verification is difficult).

Correction, September 2026: what this article got wrong and how it was fixed

On September 5, 2026 we checked this article against the FDA Orange Book, Health Canada, IQVIA and the FDA's shortage record. The head fact was wrong, and several country entries were wrong. We have corrected the text in place rather than quietly rewriting it; this note lists what changed.

Earlier statement	Corrected statement	Source
The compound patent is US 8,927,488 and expired December 5, 2023	The compound patent is US 8,129,343 and expires December 5, 2031 for Ozempic and Wegovy	FDA Orange Book, NDA 209637 and NDA 215256
Oral generics possible by 2027, injectable by 2031 to 2032	No U.S. generic in any form before December 5, 2031; Ozempic use patent to June 21, 2033; Wegovy pen patents to 2038 and 2041	FDA Orange Book
Semaglutide remains on the FDA shortage list (April 2026)	Shortage declared resolved February 21, 2025; Fifth Circuit upheld the FDA August 27, 2026	FDA
Canada's patent runs to December 2028, generics around 2029	Data protection ended January 4, 2026; first generic approved April 28, 2026; Wegovy generic June 29, 2026	CADTH table; Health Canada
India rejected the patent in 2019	Indian product patent IN262697B expired March 20, 2026; Dr. Reddy's and Torrent launched that month	ip fray, March 26, 2026
No Paragraph IV challenge has been filed	Challenges were filed and settled with Mylan/Viatris, Sun, Dr. Reddy's and Apotex in 2024	Columbia STLR, October 2024
Sandoz filed with the EMA in February 2026; Teva targets a 2027 Rybelsus generic	Not verifiable; removed. Sandoz and Teva have submissions pending at Health Canada	Health Canada; Labiotech
Ozempic lists at $968.52; compounded semaglutide averages $250 to $400	Ozempic lists at about $1,028, Wegovy at $1,349, both to $675 on January 1, 2027; compounded month-1 median $197	TrumpRx; CNBC; Compounded GLP-1 Price Index

EU patent and supplementary protection certificate dates could not be verified from a primary register and have been removed rather than replaced.

2026: the year semaglutide went generic outside the U.S.

While U.S. protection runs to 2031, eight countries lost semaglutide exclusivity in 2026 by IQVIA's count: Canada, Brazil, China, India, Mexico, Turkey, Saudi Arabia and South Africa. IQVIA describes March 2026 as the first wave. The events we could tie to a dated source as of September 5, 2026:

Country	Event	Date	Source
Canada	Data protection for semaglutide ended	January 4, 2026	CADTH table (NCBI Bookshelf)
Canada	Last listed Canadian patent date	March 20, 2026	CADTH table
India	Product patent IN262697B expired; Dr. Reddy's and Torrent (Sembolic, Semalix) launched	March 20 to 21, 2026	ip fray, March 26, 2026
Canada	Health Canada approved the first generic semaglutide, the first G7 country to do so	April 28, 2026	Health Canada news release
Canada	Apotex generic Ozempic approved for adult type 2 diabetes; seven more submissions under review at the time	May 1, 2026	Health Canada news release
Canada	Apotex Sevmia, a generic Wegovy for patients 12 and over, approved; six further submissions pending	June 29, 2026	Health Canada news release
China	In IQVIA's March 2026 wave; patent upheld by the Supreme People's Court in December 2025 before expiring	March 2026	IQVIA; news reports (patent number unverified)

Prices followed. Health Canada says generics are typically 45 to 90 percent cheaper than brand, and Canadian rules push generic injectables to 35 percent of the brand price once three generics are on the market (IQVIA). In India, IQVIA reports vials as low as $14 a month and pens at $19, up to 90 percent below brand. None of this reaches U.S. patients legally: importing these products is illegal, and product quality cannot be verified from here.

Compounded semaglutide after the shortage: what is legal, what it costs, what the FDA has logged

The sections above about the shortage exemption describe a world that ended in early 2025. The current state, as of September 5, 2026:

• Legal status. The FDA declared the semaglutide shortage resolved on February 21, 2025 (tirzepatide on December 19, 2024). Copies of Ozempic and Wegovy can no longer be compounded on shortage grounds. A 503A pharmacy may compound semaglutide for an individual patient when the prescriber documents a clinical need the approved product does not meet; a 503B outsourcing facility may not produce what is essentially a copy. Compounding trade groups challenged the FDA's determinations and lost at the Fifth Circuit on August 27, 2026.
• Safety record. The FDA had received 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide as of May 31, 2026, with dosing errors from vials and syringes a recurring theme.
• Price. Per the Compounded GLP-1 Price Index on September 3, 2026, compounded semaglutide had a month-1 (0.25 mg) median of $197 across 14 telehealth providers (range $88 to $299) and a month-4 (1 mg) median of $224 across 12 providers (range $149 to $437). Brand self-pay has come down to meet it: Wegovy pen $199 a month for a new patient's first two fills then $349, Wegovy pill $149 to $299 by dose, Ozempic pen $199 through TrumpRx.

Patents played no part in any of this. The compound patent will still be in force in 2031 whether or not a given pharmacy can compound semaglutide for a given patient.

What price the patent actually protects, and what changes on January 1, 2027

The reason people ask about patent expiry is price. The U.S. price picture as of September 5, 2026, with sources:

Product	List price	Self-pay price	Insured with savings card	Source
Ozempic pen	About $1,028 a month	$199 a month (TrumpRx)	As low as $25 with commercial coverage	TrumpRx; NovoCare
Wegovy pen	$1,349 a month	$199 a month for a new patient's first two fills (through December 31, 2026), then $349; Wegovy HD 7.2 mg $399	As low as $25, savings capped at $100 a month	wegovy.com; TrumpRx
Wegovy pill	$1,349 a month	$149 (1.5 mg), $199 (4 mg), $299 (higher strengths)	As low as $25	wegovy.com
Ozempic, Wegovy and Rybelsus from January 1, 2027	$675 a month	Self-pay programs expected to continue; not yet posted	Not yet posted	Novo Nordisk announcement, February 24, 2026 (CNBC)
Compounded semaglutide	Not applicable	Month-1 median $197, month-4 median $224	Not covered	Compounded GLP-1 Price Index, September 3, 2026

Two things follow. First, the December 2031 patent date no longer separates a $1,000 drug from a cheap one; Novo Nordisk has already halved the list price for 2027 and set self-pay at $149 to $349. Second, U.S. generic entry in 2031 to 2033 will compete against a $675 list price, not the $1,349 that existed when most patent articles were written, which changes how much further prices can fall.

Patents versus regulatory exclusivity: two clocks, and why liraglutide went generic first

The Orange Book lists two different kinds of protection for each product, and they run on different clocks.

Protection	Ozempic	Wegovy	What it blocks
Compound patent	US 8,129,343 to December 5, 2031	US 8,129,343 to December 5, 2031	Any generic semaglutide
Formulation and use patents	US 9,132,239 to February 1, 2032; US 10,335,462 to June 21, 2033	US 9,764,003 to June 21, 2033; US 11,478,533 to May 13, 2040	Copying the formulation or labeling the patented use
Device patents	Several expired January and July 2026	To August 24, 2038 and February 17, 2041	Copying the pen; a vial or different pen designs around them
Regulatory exclusivity	I-961 to January 28, 2028	I-935 to March 8, 2027; I-973 to August 15, 2028	FDA approval of a generic for the protected indication, regardless of patents

Exclusivity is FDA-granted, patent-independent, and usually shorter; it matters when it outlasts the patents, which it does not here. The template for what 2031 to 2033 will look like is liraglutide, the earlier Novo Nordisk GLP-1: Teva launched the authorized generic of Victoza on June 24, 2024 (the first generic GLP-1 in the U.S.), Hikma launched its own generic Victoza on December 26, 2024, and Teva launched generic Saxenda on August 28, 2025 at about 30 percent below brand. By March 2026, SingleCare listed generic liraglutide at $221 for three pens with a coupon against about $1,438 for the brand. Expect semaglutide to follow the same shape: an authorized generic first, then independent generics, then steep coupon discounts within a year.

FAQ

When does the main semaglutide patent expire?

The U.S. compound patent, US 8,129,343, expires December 5, 2031 for Ozempic and Wegovy, per the FDA Orange Book (seen September 5, 2026). Formulation, use and device patents extend to 2032, 2033, 2038 and 2041 depending on the product. Earlier versions of this page gave a 2023 date, which was wrong.

Can generic semaglutide be sold now that the main patent expired?

No, and the main patent has not expired: the compound patent runs to December 5, 2031. Until then no U.S. generic can launch without winning a court challenge, and Novo Nordisk settled the challenges filed by Mylan/Viatris, Sun, Dr. Reddy's and Apotex in 2024 on confidential terms.

Does patent expiration affect compounded semaglutide availability?

No. Broad compounding was legal because of the FDA shortage listing, not patents, and that listing ended on February 21, 2025 (upheld by the Fifth Circuit on August 27, 2026). Compounded semaglutide today is limited to patient-specific prescriptions with a documented clinical need.

When will generic semaglutide be available in the U.S.?

Not before December 5, 2031, when the compound patent expires, for any dosage form. Ozempic's use patent runs to June 21, 2033 and Wegovy's pen patents to 2038 and 2041, so actual launch dates depend on the confidential 2024 settlements and on which device generic makers use.

Are there generic versions available in other countries?

Yes. Health Canada approved the first generic semaglutide on April 28, 2026 and a Wegovy generic (Apotex's Sevmia) on June 29, 2026. India's product patent expired March 20, 2026 and Dr. Reddy's and Torrent launched that month. IQVIA lists eight countries losing exclusivity in 2026. Importing these products to the U.S. is illegal.

What's the difference between a generic and a biosimilar for semaglutide?

Semaglutide follows the generic (ANDA) pathway because it's a synthetic peptide, not a biologic. The term "biosimilar" is sometimes used colloquially for complex peptides, but the regulatory pathway is the ANDA process, not the 351(k) biosimilar pathway.

Will semaglutide get cheaper when patents expire?

Yes, but not immediately. Generic competition typically reduces prices by 30-50% in the first year and 70-80% after multiple generics enter. For semaglutide the U.S. patents run to December 2031, so the near-term price changes come from Novo Nordisk itself: self-pay Ozempic and Wegovy pens are $199 a month, the Wegovy pill $149, and list prices drop to $675 on January 1, 2027. Where generics launched in 2026, Health Canada reports prices 45 to 90 percent below brand.

Can Novo Nordisk extend the patents further?

Patent term extensions beyond the current dates are unlikely. The company already received the maximum allowable adjustments under U.S. patent law. New patents on improved formulations or new indications could extend protection for those specific products, but not for the current Ozempic and Wegovy formulations.

What happens if a generic manufacturer challenges the patents?

If a manufacturer files an ANDA with a Paragraph IV certification claiming the patents are invalid, it triggers a 30-month stay and likely patent infringement litigation. If the manufacturer wins, generic entry could happen years earlier than the patent expiration dates. Challenges were filed, and Novo Nordisk settled with Mylan/Viatris, Sun, Dr. Reddy's and Apotex in 2024 on confidential terms (Columbia STLR, October 2024).

Does patent expiration affect tirzepatide (Mounjaro/Zepbound)?

No. Tirzepatide is a different molecule with a separate patent portfolio. Eli Lilly's core tirzepatide patents don't expire until 2036-2037, and formulation patents extend through 2040.

Will insurance cover generic semaglutide?

Most insurance plans cover generics at a lower tier than brand-name drugs, so generic semaglutide will likely have a lower copay. However, coverage for weight-loss indications varies widely. Many commercial plans exclude weight-loss drugs regardless of generic status.

Can I stockpile compounded semaglutide before the shortage exemption ends?

Compounded semaglutide has a 28-60 day shelf life after first use depending on preservative system, so stockpiling more than 8 weeks of supply is impractical. The medication degrades over time, and using expired peptide is both less effective and potentially less safe.

Is semaglutide off patent in the United States?

No. As of September 5, 2026 the FDA Orange Book lists the semaglutide compound patent, US 8,129,343, as expiring December 5, 2031 for both Ozempic and Wegovy, with formulation, use and device patents running to 2032, 2033, 2038 and 2041. Semaglutide is off patent in Canada, India, China and several other countries as of 2026, but those generics cannot legally be imported into the U.S.

When does the Ozempic patent expire in the U.S.?

The compound patent that covers Ozempic's active ingredient expires December 5, 2031. Ozempic also carries a drug product patent to February 1, 2032, a method-of-use patent to June 21, 2033, and regulatory exclusivity I-961 to January 28, 2028, per the FDA Orange Book listing for NDA 209637 seen September 5, 2026. Several Ozempic device patents expired in January and July 2026. Actual generic launch dates also depend on Novo Nordisk's confidential 2024 settlements.

Is there a generic Ozempic in Canada?

Yes. Health Canada approved the first generic semaglutide on April 28, 2026, the first G7 country to do so, and Apotex's generic Ozempic for adult type 2 diabetes on May 1, 2026. A generic Wegovy, Apotex's Sevmia, followed on June 29, 2026, with six more submissions under review. Health Canada says generics are typically 45 to 90 percent cheaper than the brand. Bringing them into the U.S. is illegal.

Why is liraglutide generic but semaglutide is not?

Liraglutide is an older molecule whose U.S. patents ran out first. Teva launched the authorized generic of Victoza on June 24, 2024, Hikma followed on December 26, 2024, and Teva launched generic Saxenda on August 28, 2025. Semaglutide's compound patent, US 8,129,343, was filed later and carries a patent term extension to December 5, 2031, so no U.S. semaglutide generic can launch before then.

Related guides

• When Does Tirzepatide Patent Expire? The Complete Patent Cliff Timeline and What It Means for Compounded Access
• How Long Is Tirzepatide Good For: The Complete Stability Timeline for Every Formulation
• Should Semaglutide Be Refrigerated? Storage Requirements for Every Formulation
• How Long Has Semaglutide Been on the Market? A Complete Timeline from FDA Approval to 2026
• When Will Wegovy Be Generic? The Patent Timeline, FDA Pathway, and What Compounded Semaglutide Changes
• Who Owns Wegovy? The Corporate Structure, Patent Timeline, and What It Means for Compounded Semaglutide Access
• Tool: weight-loss timeline tool

Sources

1. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. FDA. 2017 (updated 2024).
2. U.S. Food and Drug Administration. Orange Book patent and exclusivity data, Ozempic NDA 209637, seen September 5, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=209637&Appl_type=N
3. U.S. Food and Drug Administration. Orange Book patent and exclusivity data, Wegovy NDA 215256, seen September 5, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=215256&Appl_type=N
4. U.S. Food and Drug Administration. Semaglutide and tirzepatide shortage resolutions and compounding policy, December 19, 2024. https://www.fda.gov/media/185577/download
5. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss, adverse-event counts as of May 31, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
6. IQVIA. Your questions answered: off-patent semaglutide in 2026, April 7, 2026. https://www.iqvia.com/locations/emea/blogs/2026/04/your-questions-answered-off-patent-semaglutide-in-2026
7. Teva. Teva announces launch of authorized generic of Victoza (liraglutide injection) in the United States, June 24, 2024. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Teva-Announces-Launch-of-Authorized-Generic-of-Victoza-liraglutide-injection-1.8mg-in-the-United-States/default.aspx
8. Health Canada. Canada approves first generic semaglutide for weight loss (Sevmia, Apotex), June 29, 2026; Canada approves second generic semaglutide, May 1, 2026 (news releases, canada.ca).
9. ip fray. Another semaglutide generic enters India as Novo Nordisk patent expires; Delhi High Court denies injunction, March 26, 2026. https://ipfray.com/another-semaglutide-generic-enters-india-as-novo-nordisk-patent-expires-delhi-high-court-denies-injunction/
10. FDA. Guidance for Industry: Compounding and the FDA. Section 503A. Updated 2022.
11. CADTH. Data protection and patent expiry dates for GLP-1 receptor agonists in Canada (table), NCBI Bookshelf NBK602920. https://www.ncbi.nlm.nih.gov/books/NBK602920/table/t03/
12. CNBC. Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50 percent ($675 from January 1, 2027), February 24, 2026. https://www.cnbc.com/2026/02/24/novo-nordisk-to-slash-wegovy-ozempic-us-list-prices-by-up-to-50percent.html
13. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed April 2026.
14. Aitken M et al. The Regulation of Prescription Drug Competition and Market Responses. Health Affairs. 2024.
15. Health Canada. Canada approves first generic semaglutide for weight loss (Sevmia), June 29, 2026; Canada approves second generic semaglutide, the first G7 country to do so, May 1, 2026 (news releases, canada.ca).
16. Columbia Science and Technology Law Review. Semaglutide patent litigation and settlements, October 2024. https://journals.library.columbia.edu/index.php/stlr/blog/view/653
17. TrumpRx. Ozempic, Wegovy and Zepbound listings with original prices, seen September 5, 2026. https://trumprx.gov
18. Novo Nordisk. What to pay for Wegovy, seen September 5, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
19. FormBlends. Compounded GLP-1 Price Index, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer.